Cargando…

CCR5 and CXCR4 antagonist and agonist binding sites

Detalles Bibliográficos
Autores principales:	Teintze, Martin, Wilkinson, Royce, Grieco, Paul, Mills, John, Dratz, Edward
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2006
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1716948/ http://dx.doi.org/10.1186/1742-4690-3-S1-S39

Ejemplares similares

Short-term variation of HIV tropism readouts in the absence of CCR5 antagonists
por: Brumme, CJ, et al.
Publicado: (2010)

Effect of 24 weeks of intensification with a CCR5-antagonist on the decay of the HIV-1 latent reservoir
por: Díaz, L, et al.
Publicado: (2010)

Co-receptor usage prediction at quasispecies level using ultra-deep pyrosequencing on both circulating and proviral hiv in patients candidates to CCR5 antagonist treatment
por: Abbate, Isabella, et al.
Publicado: (2010)

Humanized anti CCR4 antibody KW0761 targets HTLV-1 infected CD4+ CCR4+ and CD8+CCR4+ T cells to treat HAM/TSP
por: Yamano, Yoshihisa, et al.
Publicado: (2015)

Clearing the HIV reservoir by transplanting CCR5 deficient stem cells
por: Hütter, Gero
Publicado: (2011)

The global distribution of CCR5 delta 32 polymorphism: role in HIV-1 protection
por: Gupta, Anuroopa, et al.
Publicado: (2012)

Therapeutic Perspectives of HIV-Associated Chemokine Receptor (CCR5 and CXCR4) Antagonists in Carcinomas
por: González-Arriagada, Wilfredo Alejandro, et al.
Publicado: (2022)

Chemokine receptor CCR5 mediates resistance to West Nile Virus infection in mouse and man
por: Murphy, Philip
Publicado: (2006)

Monoclonal antibodies and small-molecules as distinct subclasses of CCR5-targeted therapies for HIV-1
por: Olson, William C
Publicado: (2006)

Human and chicken antibodies to CCR5-ECL1 block mucosal and systemic HIV infection
por: Lopalco, Lucia, et al.
Publicado: (2006)

Recombinant soluble CCR5 AND CXCR4 chemokine receptors as anti-HIV drug targets
por: Kurbatska, Victoria, et al.
Publicado: (2010)

Spermine and spermidine bind CXCR4 and inhibit CXCR4- but not CCR5-tropic HIV-1 infection
por: Harms, Mirja, et al.
Publicado: (2023)

Establishment of a novel CCR5 and CXCR4 expressing CD4(+ )cell line which is highly sensitive to HIV and suitable for high-throughput evaluation of CCR5 and CXCR4 antagonists
por: Princen, Katrien, et al.
Publicado: (2004)

Expression and function of the chemokine, CXCL13, and its receptor, CXCR5, in AIDS-associated non-Hodgkin's lymphoma
por: Widney, DP, et al.
Publicado: (2009)

Development of a CCR5-tropic HIV-1 fusion inhibition assay amenable to high-throughput screening for topical microbicides
por: Beer, B, et al.
Publicado: (2006)

Macrocyclic polyamines inhibit HIV infection by interacting with the cellular HIV co-receptors CXCR4 and CCR5
por: Schols, Dominique, et al.
Publicado: (2009)

Mogamulizumab, an anti-CCR4 monoclonal antibody, is a potent therapeutic option for adult T-cell leukemia-lymphoma
por: Utsunomiya, Atae
Publicado: (2014)

Anti-CCR4 antibody activates virus specific immune response in STLV-1 infected Japanese monkey
por: Sugata, Kenji, et al.
Publicado: (2015)

Identification of human monoclonal antibodies specific for CCR5 from an antibody library derived from HIV-infected long-term non-progressors
por: Zhang, Mei-Yun, et al.
Publicado: (2006)

In silco analysis of carboxamide derivatives of piperidine as potential antagonists of CCR5
por: Harishchander, A, et al.
Publicado: (2014)

CCR6 mediates the intracellular HIV inhibitory activity of human beta-defensin 2
por: Sun, Lingling, et al.
Publicado: (2006)

Role of anti-CD4-binding site antibodies in modulating gp120-specific CD4 T cell and antibody responses
por: Visciano, ML, et al.
Publicado: (2006)

Influence of amount and percentage of CXCR4-using virus in predicting week 48 responses to maraviroc in treatment-naïve patients
por: Valdez, H, et al.
Publicado: (2010)

How does the location of a satellite screening site affect uptake?
por: Wilkinson, LS, et al.
Publicado: (2008)

Chemokines in rheumatoid arthritis: novel, potential therapeutic targets of the CCR2 chemokine receptor signaling pathway
por: Matsushima, K, et al.
Publicado: (2003)

The functional antagonist Met-RANTES: A modified agonist that induces differential CCR5 trafficking
por: Kiss, Debra L., et al.
Publicado: (2009)

CCR9+ and CD103+ tolerogenic dendritic cell populations in food allergy patients undergoing oral immunotherapy
por: Garcia, Marco, et al.
Publicado: (2011)

S180: RESULTS OF A PHASE 3 TRIAL OF AN ORAL CXCR4 ANTAGONIST, MAVORIXAFOR, FOR TREATMENT OF PATIENTS WITH WHIM SYNDROME
por: Badolato, Raffaele, et al.
Publicado: (2023)

A gain-of-function CCR4 mutations in adult T-cell leukemia/lymphoma (ATL) enhance the chemotactic abilities and P13K/AKT activation
por: Nakagawa, Masao, et al.
Publicado: (2015)

Baseline HIV-1 tropism prediction in advanced immune suppressed patients: evidence of CXCR4 viruses in IDUs infected with recombinant forms
por: Paraschiv, Simona, et al.
Publicado: (2014)

Discovery and characterization of novel small-molecule CXCR4 receptor agonists and antagonists
por: Mishra, Rama K., et al.
Publicado: (2016)

CCR3, CCR4, CCR5, and CXCR3 expression in peripheral blood CD4+ lymphocytes in gastric cancer patients
por: Andalib, Alireza, et al.
Publicado: (2013)

Prognostic value of immunoexpression of CCR4, CCR5, CCR7 and CXCR4 in squamous cell carcinoma of tongue and floor of the mouth
por: Domingueti, Catherine-Bueno, et al.
Publicado: (2019)

Structural basis of dimerization of chemokine receptors CCR5 and CXCR4
por: Di Marino, Daniele, et al.
Publicado: (2023)

KSHV infection of endothelial cells manipulates CXCR7-mediated signaling: implications for Kaposi’s Sarcoma progression and intervention
por: Vomaske, Jennifer, et al.
Publicado: (2012)

Structural basis for germline gene usage of a potent class of antibodies targeting the CD4 binding site of HIV-1 gp120
por: West, AP, et al.
Publicado: (2012)

Filling the Gaps in Antagonist CCR5 Binding, a Retrospective and Perspective Analysis
por: Amerzhanova, Yerkezhan, et al.
Publicado: (2022)

The C5 region of HIV-1 gp120 binds specific
por: Dalgleish, A, et al.
Publicado: (2006)

Back to the cell cycle with SAMHD1 and its viral antagonist, Vpx
por: Margottin-Goguet, Florence
Publicado: (2013)

Proteomic and Systems Biology Analysis of Monocytes Exposed to Securinine, a GABA(A) Receptor Antagonist and Immune Adjuvant
por: Shipman, Matt, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_h16v43rmv3ip6o5hj0des6egdv